Genmab, Incyte Announce KRAS G12D Colorectal Trial
Genmab and Incyte will collaborate on a Phase 1/2 trial testing petosemtamab, INCB161734 and standard chemotherapy as first-line treatment for metastatic colorectal cancer with a KRAS G12D mutation. Genmab will lead the study, while Incyte will co-fund it and supply its investigational KRAS G12D inhibitor; the combination brings together therapies aimed at different cancer targets in a patient group with substantial unmet medical need. The trial expands Incyte’s KRAS G12D research into another gastrointestinal cancer and adds a new development program, though its impact will depend on results from the study.




